

1 **Efficacy of multilevel exercise programmes with different intensities on development**
2 **and metabolic homeostasis in overweight and obese children: study protocol for a**
3 **randomized controlled trial**

4

5 Yimin Zhao^{1, #}, Chao Liu^{2, #}, Jiaying Wang², Yangong Liu², Haiyi Yu², Tianqi Chang², Chenyu
6 Fan², Wenxiu Wang¹, Yueying Li¹, Hu Wang², Yuzhou Xue², Wei Zhao^{2, 4}, Chuan Ren², Ligang
7 Cui³, Xinheng Feng², He Huang⁸, Dongwei Fan⁵, Xiang Yao⁶, Tongyan Han⁷, Tao Huang¹, and
8 Ming Xu^{2, *}

9

10 ¹ Department of Epidemiology and Biostatistics, School of Public Health, Peking University,
11 Beijing, China;

12 ²Department of Cardiology, Institute of Vascular Medicine, NHC Key Laboratory of
13 Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular
14 Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular
15 Receptors Research, Peking University Third Hospital, Beijing, China;

16 ³ Department of Ultrasound, Peking University Third Hospital, Beijing, China;

17 ⁴ Physical Examination Center, Peking University Third Hospital, Beijing, China;

18 ⁵ Department of Orthopedics, Peking University Third Hospital, Beijing, China;

19 ⁶ School of Psychological and Cognitive Sciences, Peking University, Beijing, China;

20 ⁷ Department of Pediatrics, Peking University Third Hospital, Beijing, China.

21 ⁸ Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and
22 Integrative Biology, Shanghai, China

23

24 #Yimin Zhao and Chao Liu contributed equally to this work.

25

26 **Corresponding authors:**

27 Ming Xu, MD, PhD

28 Department of Cardiology, Institute of Vascular Medicine, NHC Key Laboratory of

29 Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular

30 Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular

31 Receptors Research, Peking University Third Hospital, Beijing, China

32 Email: xuminghi@bjmu.edu.cn

33 **Abstract**

34 **Background:** The prevalence of childhood obesity is rapidly increasing worldwide. Exercise
35 has been suggested as the primary approach to manage body weight, but an effective
36 exercise program tailored for school-age children is still lacking.

37 **Objective:** This trial aims to evaluate the efficacy of a novel multilevel (children, families, and
38 schools)-coordinated exercise programmes with different intensities on adiposity and
39 development among overweight and obese school-age children. It also aims to elucidate the
40 complex interplays between the exercise interventions, multi-omic biomarkers, development,
41 and metabolic homeostasis.

42 **Methods:** This is a multilevel -coordinated two-stage randomized double-blind controlled trial,
43 comprising 366 overweight and obese children aged between 8 and 12 years from two
44 elementary schools in Beijing, China. The novel multilevel exercise programs involve families
45 and schools monitoring children's exercise and diet via a specially designed smartphone
46 application. The children will be randomly assigned to receive three school-based exercise
47 programmes (exercise intervention stage), namely low-intensity exercise, moderate-intensity
48 exercise, and intermittent vigorous exercise, for 12 weeks, followed by a 9-month
49 post-intervention follow-up (follow-up stage). The primary outcomes of this trial are the
50 changes in adiposity, development, and metabolic homeostasis during the two stages. The
51 secondary outcomes include but are not restricted to genomics and changes in blood
52 metabolomics, gut microbiota, and exercise performance.

53 **Discussion:** This trial has been approved by the ethics committee of Peking University Third
54 Hospital (ethnic approval number 2021-283-08). The findings of this trial will help establish

55 specialized multilevel coordinated school-based exercise programmes for overweight and
56 obese school-age children in China and quantitatively and qualitatively evaluate the efficacy
57 of the novel interventions.

58 **Trial registration:** This trial was prospectively registered at ClinicalTrials.gov with the
59 identifier of NCT04984005 on July 21, 2021.

60

61 **Introduction**

62 The prevalence of childhood obesity is rapidly increasing worldwide. According to recent data,
63 the number of obese children and adolescents has increased from 11 million in 1975 to 124
64 million in 2016.^{1 2} This issue is becoming particularly prevalent in developing countries such
65 as China, where the prevalence of childhood obesity and related non-communicable chronic
66 diseases is rising rapidly.³ It is projected that by 2030, 6.64 million children under the age of
67 seven, and 18.91 million children over the age of seven in China, will be obese.^{4 5} In Beijing,
68 the prevalence of overweight and obesity was found to be 17.6% and 29.1% in boys and 17.6%
69 and 18.0% in girls aged between 6 to 18 years, respectively.⁵

70

71 Childhood obesity has been linked to an increased risk of type 2 diabetes, heart disease, and
72 chronic kidney disease in later life.⁶⁻¹⁰ While exercise intervention remains the primary
73 approach for managing body weight, it may not achieve sustained desirable body weight
74 reduction on its own for obese children who also have to manage academic stress.¹¹⁻¹⁴ Indeed,
75 a recent multicomponent lifestyle intervention successfully reduced adiposity and obesity
76 prevalence among children.⁴ However, whether the involvement of schools and families could
77 improve the effectiveness of exercise intervention among school-age obese children is still
78 less studied.¹⁵ Notably, the parents and teachers may hold the opinions that strict exercise
79 intervention may impede growth and development and academic performance of the children,
80 thus reducing the effectiveness of exercise. In addition, it remains unknown whether a more
81 intense exercise programme would bring about additional health benefits in terms of
82 development and metabolic homeostasis beyond body weight during puberty for obese

83 children.^{1 14}

84

85 In this study, we aim to compare the effects of multilevel-coordinated exercise programmes

86 with different intensities on adiposity, development, and metabolic homeostasis, as well as

87 related mechanisms. Specifically, we aim to determine which exercise programme is more

88 effective in reducing body weight and improving development and metabolic homeostasis

89 among overweight and obese children, as well as identifying the factors that mediate

90 exercise-induced changes in these areas. Additionally, we aim to establish a regionally

91 representative school-family-hospital evaluation model for exercise intervention.

92

93 **Method and Analysis**

94 **Trial design**

95 This is a multilevel coordinated (children, families, and schools) two-stage 12-month

96 three-arm randomized double-blind controlled trial.

97

98 **Methods: Participants, interventions, and outcomes**

99 This protocol is reported following the guidelines of the Standard Protocol Items:

100 Recommendations for Interventional Trials (SPIRIT) 2013 Statement.¹⁶

101

102 **Study setting**

103 This trial will be conducted in two government-funded elementary schools in Beijing, the

104 capital city of China. The steering committee of this study included paediatricians, physicians,

105 epidemiologists, and statisticians from Peking University Third Hospital and School of Public
106 Health at Peking University. All study procedures will be performed in accordance with the
107 Declaration of Helsinki.

108

109 **Eligibility criteria**

110 Eligible participants must meet the following inclusion criteria:

- 111 1) overweight or obese (see **Table 1** for age- and sex-specific BMI cutoff points);
- 112 2) 8 to 12 years old;
- 113 3) did not participate in any weight loss programmes, including medication, exercise, and
114 lifestyle modification, within the last three months before baseline assessment;
- 115 4) provide written informed consent by both themselves and their statutory guardians.

116

117 Participants will be excluded if they have any of the following conditions:

- 118 1) have any severe chronic disease, including asthma, cardiovascular disease, and cancer.
- 119 2) have drug-induced secondary obesity;
- 120 3) have Cushing syndrome, Prader-Willi syndrome, or other medical conditions that may
121 lead to obesity;
- 122 4) have intellectual, mental, or behavioural disorders;
- 123 5) feel difficulty communicating with physical education (PE) teachers, paediatricians, and
124 physicians;
- 125 6) have any other conditions that may prevent exercising safely, which will be assessed by
126 paediatricians and physicians.

127

128 **Who will take informed consent?**

129 A group of research staff, including paediatricians and physicians, will collect written informed
130 consent from both children and their statutory guardians before evaluating the eligibility of
131 potential participants. During the consent process, potentially eligible participants and their
132 parents will be notified that this trial will require the collection of fasting blood, urine, and
133 faeces samples.

134

135 **Interventions**

136 **Explanation for the choice of comparators**

137 Eligible participants will be randomly assigned into three groups receiving low-intensity
138 exercise, moderate-intensity exercise, and intermittent vigorous exercise, respectively. The
139 low-intensity exercise is chosen as the comparator because exercise intervention, even at a
140 low intensity, has been proven effective in improving energy expenditure and cardiometabolic
141 health among children and adolescents. The novel intervention programmes emphasize the
142 involvement of family and school to assist children's exercise and food intake using a
143 specifically designed smartphone application. The health educators, the pediatrician in the
144 school hospital, will be trained by the project staff before the intervention. During the
145 intervention, the health educator will deliver two health education sessions, including exercise
146 and healthy eating, to children every month. Family members and school PE teachers at each
147 site will be separately invited to attend the health education sessions two times per month,
148 where the project staff shared the information on children's exercise performance and

149 strengthened the family and school involvement to assist children's exercise.

150

151 **Intervention description**

152 The levels of intensity will be determined according to the percentages of heart rate reserve
153 (HRR) during exercise, which is calculated by deducting the resting heart rate (HR_{resting}) from
154 the maximum heart rate (HR_{max}).^{17 18} The HR_{resting} and the HR_{max} will be evaluated on a
155 COSMED Quark PFT pulmonary function testing system in Peking University Third Hospital at
156 baseline.

157

158 All participants will engage in a school-based exercise programme, instructed by PE teachers,
159 at the frequency of 30 minutes/time × two times/day × three days/week for 12 weeks. Each
160 30-minute exercise will comprise a 7-minute warm-up session, a 16-minute exercise session,
161 and a 7-minute cool-down session. In the warm-up and cool-down sessions, all groups of
162 participants will do walking and stretching exercises, including arm circles, overhead arm
163 reaches, and hip rotations, to reach a target heart rate of around $0.3 \times HRR + HR_{\text{resting}}$. During
164 the 16-minute exercise session:

165 1) for the low-intensity exercise group, the participants will be instructed to take 800-meter
166 quick walking and high knees to reach a target heart rate between $0.3 \times HRR + HR_{\text{resting}}$
167 and $0.4 \times HRR + HR_{\text{resting}}$;

168 2) for the moderate-intensity exercise group, the participants will be instructed to take
169 30-meter S-shaped quick walking, 30-meter S-shaped running, and 800-meter alternating
170 between running and walking to reach a target heart rate between $0.4 \times HRR + HR_{\text{resting}}$

171 and $0.69 \times \text{HRR} + \text{HR}_{\text{resting}}$;

172 3) for the intermittent vigorous exercise group, the participants will be instructed to take
173 various 30-second jumping and quick running activities to reach a target heart rate
174 between $0.7 \times \text{HRR} + \text{HR}_{\text{resting}}$ and $0.85 \times \text{HRR} + \text{HR}_{\text{resting}}$, divided by a 60-second
175 relaxation above $0.6 \times \text{HRR} + \text{HR}_{\text{resting}}$.

176

177 In the 2-week run-in period prior to intervention period, all participants will receive the same
178 low-intensity exercise intervention as described above.

179

180 **Criteria for discontinuing or modifying allocated interventions**

181 We allow participants to discontinue the exercise intervention at any time for any reason. The
182 research staff will document the reasons for dropping out if provided by the participants. We
183 will not recruit new participants to fill the vacancy after the implementation of the exercise
184 intervention.

185

186 **Strategies to improve adherence to interventions**

187 Participants will be instructed to wear a calibrated smartwatch (Huawei Band 6) during the
188 run-in and intervention stages, which is provided by Huawei Technologies for free. During
189 each 30-minute exercise session, the smartwatch will return 30 reads of real-time heart rate at
190 a 1-minute interval. Adherence to the exercise programme is assessed by counting the
191 real-time heart rate reads that are within the target range for each participant. We assume that
192 all 16 reads collected during the 16-minute exercise session are located within the target

193 heart rate zone in each group. In addition, we will reward participants who satisfactorily
194 complete the 12-week exercise intervention with a gift, including a pen and pencil box.

195

196 **Relevant concomitant care permitted or prohibited during the trial**

197 During the 2-week run-in period and 12-week exercise intervention period, all participants will
198 be instructed to maintain their usual physical activity and diet using the specifically designed
199 smartphone application. We will monitor their diet compositions via a three-day dietary recall,
200 and the nutrient intake will be analyzed according to China Food Composition Tables.¹⁹ We
201 will assess their physical activity, excluding exercise intervention, via the Huawei band 6.
202 These two questionnaires will be performed by trained research staff face-to-face. In addition,
203 participants and their parents will receive notifications via a mobile phone application, which
204 will notify the participants to maintain their usual diet and physical activity.

205

206 **Provisions for post-trial care**

207 We will implement a 9-month post-intervention follow-up to observe the dynamic changes in
208 adiposity among the participants.

209

210 **Outcomes**

211 **Primary outcomes**

212 The primary outcomes of this trial are the changes in adiposity and biomarkers of
213 development and homeostasis, including anthropometric measurements, sexual hormones,
214 body compositions, cardiopulmonary functions, and biochemical measurements.

215

216 **Secondary outcomes**

217 Secondary outcomes include changes in:

- 218 1. Exercise performance;
- 219 2. Hepatic hemodynamic index;
- 220 3. Bone mineral density;
- 221 4. Inflammatory biomarkers;
- 222 5. Thyroid function;
- 223 6. Oxidative stress biomarkers;
- 224 7. Oral and gut microbiota;
- 225 8. Blood and faecal metabolomics;
- 226 9. Flow-mediated dilation
- 227 10. Attention performance;
- 228 11. Sleep quality;
- 229 12. Diets and nutrients;
- 230 13. Whole genome sequencing;
- 231 14. Viromics;
- 232 15. Proteomics;
- 233 16. Volatile organic compounds in breath;

234

235 **Participant timeline**

236 **Figure 1** shows the schedule of enrollment, allocation, interventions, and assessments.

237

238 **Sample size**

239 We estimated the sample size using the following equation:

$$N_d = \frac{1641.6 \times \lambda}{(\sin^{-1}\sqrt{p_{max}} - \sin^{-1}\sqrt{p_{min}})^2}$$

240 , where N_d is the minimum sample size, P_{max} and P_{min} are the highest and lowest cure rates,

241 and λ depends on α , β , and degree of freedom. In this trial, α is 0.05, β is 0.1, and the degree

242 of freedom is 2. Thereby, λ is 12.65. We assumed that 65%, 50%, and 40% of overweight and

243 obese participants that receive low-intensity exercise, moderate-intensity exercise, and

244 intermittent vigorous exercise would successfully lower their body weight, achieving a healthy

245 BMI, respectively. A minimum sample size of 122 is required for each group accounting for a

246 10% drop-out rate. A total of 366 children will be included in this trial.

247

248 **Recruitment**

249 From January to March 2022, we included two elementary schools in Beijing by inviting the

250 school principals to participate in this trial. The two schools agreed with the study protocol. We

251 will recruit eligible participants, aged between 8 and 12 years, from seven school campuses.

252 All students and their parents (or their statutory guardians) will receive an advertisement for

253 this trial from the principal and their PE teachers. Potential eligible participants who provide

254 written informed consent by themselves and statutory guardians will be asked to complete a

255 nurse-administrated questionnaire concerning their health-related information and undergo a

256 physical examination according to standard operating procedure.

257

258 **Assignment of interventions: allocation**

259 **Sequence generation**

260 We will perform sex- and BMI-stratified randomization via computer-generated random
261 numbers.

262

263 **Concealment mechanism**

264 The participants will be randomized using a computer-generated random sequence, which will
265 be sealed in an envelope until the end of this trial.

266

267 **Implementation**

268 An independent statistician from the School of Public Health, Peking University, who will not
269 participate in recruitment, allocation, baseline assessment, and intervention, will conduct the
270 randomization.

271

272 **Assignment of interventions: Blinding**

273 **Who will be blinded**

274 All participants, their parents, the PE teachers, the paediatricians, the physicians, and the
275 statisticians will be blinded to the allocation.

276

277 **Procedure for unblinding if needed**

278 Not applicable to this trial.

279

280 **Data collection and management**

281 **Plans for assessment and collection of outcomes**

282 All data will be collected and processed according to standard operating procedures. The
283 demographic information of participants will be collected at baseline. Trained nurses will
284 conduct the physical examination under the supervision of paediatricians. The biochemical
285 measurements will be conducted at the clinical laboratory of Peking University Third Hospital.
286 The oral and gut microbiota compositions will be analyzed using the QIIME2 pipeline
287 (<https://qiime2.org>). The metabolomics analysis will be conducted on a liquid
288 chromatography-electrospray ionization tandem mass spectrometry system (QTRAP 6500+
289 system).^{20,21} Diet will be evaluated via a 3-day diet recall at baseline and at the end of
290 intervention period. Meanwhile, the participants will be instructed to take photo of meals to
291 facilitate nutrient intake analysis. Nutrients intake will be analyzed according to the China
292 Food Composition Tables by two independent investigators.¹⁹

293

294 **Plans to promote participant retention and complete follow-up**

295 No other strategy is planned to promote participant retention and complete follow-up.

296

297 **Data management**

298 A double entry and validation approach is planned for data management. The personal
299 information and medical records of each participant will be kept in an individual folder and
300 stored in a secure storage area at the School of Public Health, Peking University. We will
301 return the results of the physical examination and laboratory biochemical measurement to

302 participants at the end of the exercise intervention/follow-up.

303

304 **Confidentiality**

305 The personal information and medical records of participants will be treated as strictly
306 confidential. The research team will ensure the privacy and confidentiality of the personal
307 information and medical records of participants and store all data in an encrypted database
308 with all identifiers removed.

309

310 **Plans for collection, laboratory evaluation and storage of biological specimens for** 311 **genetic or molecular analysis in this trial/future use**

312 At baseline and the end of exercise intervention, 6 mL overnight fasting venous blood will be
313 collected by trained nurses from Peking University Third Hospital under the supervision of a
314 paediatrician. The participants will also provide urine and faeces samples. All biospecimens
315 will be immediately delivered to the clinical laboratory of Peking University Third Hospital and
316 stored at -80°C until analysis.

317

318 **Statistical methods**

319 **Statistical methods for primary and secondary outcomes**

320 Statistical analysis will be performed using Stata/MP version 17.0 by statisticians from Peking
321 University Health Science Center, which will not participate in participant enrollment,
322 allocation, and exercise intervention. The intention-to-treatment analysis will be used, which
323 includes all participants who complete the baseline assessment and is subject to

324 randomization and exercise intervention. Between-group differences in continuous and
325 categorical variables at baseline will be analyzed using one-way analysis of variance and
326 chi-square test, respectively. Within-group changes from baseline to the end of the
327 intervention will be analyzed using paired t test for each group. Between-group differences of
328 changes in the continuous variables will be analyzed using one-way ANOVA, one-way
329 analysis of covariance, or Mann-Whitney rank sum test when appropriate. Correlations of
330 changes in continuous variables will be analyzed using Pearson's or Spearman's correlation
331 analysis when appropriate. Statistical significance is set at $\alpha = 0.05$.

332

333 **Interim analyses**

334 No interim analysis will be performed due to the short duration of this trial.

335

336 **Methods for additional analyses (e.g. subgroup analyses)**

337 In the sensitivity analysis, per protocol analysis is planned for participants that satisfactorily
338 complete both the baseline assessment and the two-stage intervention.

339

340 **Methods in analysis to handle protocol non-adherence and any statistical methods to**

341 **handle missing data**

342 Missing covariates will be estimated using the multiple imputation method.

343

344 **Plans to give access to the full protocol, participant level-data and statistical code**

345 Access to the full study protocol, participant-level data, and statical codes will be granted for

346 authorized research staff and will not be publicly available.

347

348 **Oversight and monitoring**

349 **Composition of the coordinating centre and trial steering committee**

350 The principal investigator (Prof. Ming Xu in the author list) has full responsibility for the design

351 and conduct of the trial. The steering committee is responsible for agreeing on the final

352 protocol and reviewing the progress of the trial and potential changes to the protocol.

353

354 **Composition of the data monitoring committee, its role and reporting structure**

355 The data monitoring committee is composed of pedestrians and statisticians and is

356 responsible for assessing adherence to exercise intervention of each participant, monitoring

357 and reporting any adverse events during exercise intervention.

358

359 **Adverse event reporting and harms**

360 The research team is responsible for reporting any adverse events. During exercise

361 intervention days, a field team comprised of a paediatrician (or a physician) and a research

362 staff from the site management organization will be sent to each school to deal with potential

363 adverse events. The PE teachers and other elementary school teachers will assist in

364 addressing potential anxiety and mood issues during exercise intervention. All severe adverse

365 events will be reported to the ethics committee of Peking University Third Hospital, which will

366 decide whether to continue or terminate this trial.

367

368 **Frequency and plans for auditing trial conduct**

369 The principal and lead investigators will meet biweekly to review the progress of the trial and
370 audit the trial conduct.

371

372 **Plans for communicating important protocol amendments to relevant parties (e.g. trial
373 participants, ethical committees)**

374 Any amendments to the study protocol must receive approval from the Ethics Committee of
375 Peking University Third Hospital. All participants, their parents, PE teachers, and research
376 staff will be promptly informed of any changes made to the study protocol. In case of a
377 potential COVID-19 outbreak in the school, the intervention will be suspended and resumed in
378 compliance with the school and government policies.

379

380 **Dissemination plans**

381 The results of this trial will be presented at domestic and international conferences and
382 published in peer-reviewed academic journals. Progress and final reports will be submitted to
383 the funding agency and regulatory bodies.

384

385 **Conclusions**

386 The present trial will provide a novel multilevel-coordinated exercise intervention targeting
387 obese and overweight children. This study aims to yield quantitative and qualitative results
388 which will shed light on the effectiveness of multi-level exercises with various intensities in
389 promoting cardiometabolic fitness and reducing adiposity in overweight and obese

390 school-aged children. Moreover, this study will utilize a multi-omic approach and systematic
391 epidemiological design to investigate the possible molecular mechanisms of the exercise
392 intervention in modulating adiposity at multiple levels. The outcomes of this trial will offer
393 clinical evidence for establishing bodyweight management guidelines for Chinese schools.

394

395 **Trial status**

396 This trial has been registered at ClinicalTrials.gov with the identifier NCT04984005.

397

398 **Acknowledgements**

399 Our special thanks go to the children, parents and physical education teachers who are
400 participating in this study. We also acknowledge the ethics committee of Peking University
401 Third Hospital. We thank Huawei Technologies Co., Ltd. for donating the smartwatch and the
402 technical support of the Huawei Research platform to this study. We also thank Beijing BOE
403 Health Technology Co., Ltd. for providing the equipment for the physical examination.

404

405 **Author contributions**

406 YZ, CL, TH, and MX contributed to conception and design of the study. JW, YL, and HY
407 organized the database. YZ, CL, TC, CF, WW, YL, HW, YX, WZ, CR LC, XF, DF, HH, XY, and
408 TH performed the study. YZ and CL wrote the first draft of the manuscript. All authors
409 contributed to manuscript revision, read, and approved the submitted version.

410

411 **Funding**

412 This trial is funded by National Key Research and Development Program (grant numbers:
413 2020YFA0803803 and 2020YFA0803800) and CAMS Innovation Fund for Medical Sciences
414 (grant number: 2021-I2M-5-003).

415

416 **Availability of data and materials**

417 Study data will be available from the principal investigator upon reasonable request and will
418 not be made publicly available.

419

420 **Ethics approval and consent to participate**

421 This study has been approved by the ethics committee of Peking University Third Hospital
422 (ethic approval number 2021-283-08).

423

424 **Consent for publication**

425 Not applicable.

426

427 **Competing interests**

428 The authors declare no competing interests.

429

430 **References**

- 431 1. Jebeile H, Kelly AS, O'Malley G, et al. Obesity in children and adolescents: epidemiology, causes,
432 assessment, and management. *The lancet Diabetes & endocrinology* 2022;10(5):351-65. doi:
433 10.1016/s2213-8587(22)00047-x [published Online First: 2022/03/07]
- 434 2. Di Cesare M, Sorić M, Bovet P, et al. The epidemiological burden of obesity in childhood: a worldwide
435 epidemic requiring urgent action. *BMC Med* 2019;17(1):212. doi: 10.1186/s12916-019-1449-8
436 [published Online First: 2019/11/26]

- 437 3. Gupta N, Goel K, Shah P, et al. Childhood obesity in developing countries: epidemiology,
438 determinants, and prevention. *Endocr Rev* 2012;33(1):48-70. doi: 10.1210/er.2010-0028
439 [published Online First: 2012/01/14]
- 440 4. Liu Z, Gao P, Gao AY, et al. Effectiveness of a Multifaceted Intervention for Prevention of Obesity in
441 Primary School Children in China: A Cluster Randomized Clinical Trial. *JAMA Pediatr*
442 2022;176(1):e214375. doi: 10.1001/jamapediatrics.2021.4375 [published Online First:
443 2021/11/09]
- 444 5. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China. *The lancet Diabetes &*
445 *endocrinology* 2021;9(6):373-92. doi: 10.1016/s2213-8587(21)00045-0 [published Online First:
446 2021/05/23]
- 447 6. Flynn JT, Urbina EM, Brady TM, et al. Ambulatory Blood Pressure Monitoring in Children and
448 Adolescents: 2022 Update: A Scientific Statement From the American Heart Association.
449 *Hypertension (Dallas, Tex : 1979)* 2022;79(7):e114-e24. doi: 10.1161/hyp.000000000000215
450 [published Online First: 2022/05/24]
- 451 7. Myette RL, Feber J, Blinder H, et al. Blood pressure variability in children with obesity and
452 sleep-disordered breathing following positive airway pressure treatment. *Pediatr Res*
453 2022;92(3):810-15. doi: 10.1038/s41390-021-01841-8 [published Online First: 2021/11/18]
- 454 8. Chrysaidou K, Kotsis V, Chainoglou A, et al. Impact of ambulatory SBP and overweight on executive
455 function performance in children and adolescents. *Journal of hypertension* 2020;38(6):1123-30.
456 doi: 10.1097/hjh.0000000000002371 [published Online First: 2020/05/07]
- 457 9. Twig G, Tirosch A, Leiba A, et al. BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide
458 Cohort of 2.3 Million Adolescents. *Diabetes care* 2016;39(11):1996-2003. doi:
459 10.2337/dc16-1203 [published Online First: 2016/10/14]
- 460 10. Twig G, Yaniv G, Levine H, et al. Body-Mass Index in 2.3 Million Adolescents and Cardiovascular
461 Death in Adulthood. *N Engl J Med* 2016;374(25):2430-40. doi: 10.1056/NEJMoa1503840
462 [published Online First: 2016/04/14]
- 463 11. Martin A, Booth JN, Laird Y, et al. Physical activity, diet and other behavioural interventions for
464 improving cognition and school achievement in children and adolescents with obesity or
465 overweight. *Cochrane Database Syst Rev* 2018;3(3):Cd009728. doi:
466 10.1002/14651858.CD009728.pub4 [published Online First: 2018/03/03]
- 467 12. Cadenas-Sanchez C, Idoate F, Cabeza R, et al. Effect of a Multicomponent Intervention on Hepatic
468 Steatosis Is Partially Mediated by the Reduction of Intermuscular Abdominal Adipose Tissue in
469 Children With Overweight or Obesity: The EFIGRO Project. *Diabetes care* 2022;45(9):1953-60.
470 doi: 10.2337/dc21-2440 [published Online First: 2022/09/01]
- 471 13. Wang Y, Wang K, Du M, et al. Maternal consumption of ultra-processed foods and subsequent risk
472 of offspring overweight or obesity: results from three prospective cohort studies. *Bmj*
473 2022;379:e071767. doi: 10.1136/bmj-2022-071767 [published Online First: 2022/10/06]
- 474 14. Hargreaves D, Mates E, Menon P, et al. Strategies and interventions for healthy adolescent growth,
475 nutrition, and development. *Lancet (London, England)* 2022;399(10320):198-210. doi:
476 10.1016/s0140-6736(21)01593-2 [published Online First: 2021/12/03]
- 477 15. Mead E, Brown T, Rees K, et al. Diet, physical activity and behavioural interventions for the
478 treatment of overweight or obese children from the age of 6 to 11 years. *Cochrane Database*
479 *Syst Rev* 2017;6(6):Cd012651. doi: 10.1002/14651858.Cd012651 [published Online First:
480 2017/06/24]

- 481 16. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for
482 protocols of clinical trials. *Bmj* 2013;346:e7586. doi: 10.1136/bmj.e7586 [published Online First:
483 2013/01/11]
- 484 17. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in
485 patients with cardiovascular disease. *European heart journal* 2021;42(1):17-96. doi:
486 10.1093/eurheartj/ehaa605 [published Online First: 2020/08/30]
- 487 18. Blair SN, Gibbons LW. Guidelines for exercise testing and prescription. *Journal of Cardiopulmonary*
488 *Rehabilitation and Prevention* 1986;6(8):315-16.
- 489 19. Yang Y. China Food Composition Table2002.
- 490 20. Zhang F, Wan Y, Zuo T, et al. Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine
491 Biosynthesis in Gut Microbiome in Patients With COVID-19. *Gastroenterology*
492 2022;162(2):548-61.e4. doi: 10.1053/j.gastro.2021.10.013 [published Online First: 2021/10/24]
- 493 21. Yuan M, Breitkopf SB, Yang X, et al. A positive/negative ion-switching, targeted mass
494 spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue.
495 *Nat Protoc* 2012;7(5):872-81. doi: 10.1038/nprot.2012.024 [published Online First: 2012/04/14]
- 496 22. China BNHCotPsRo. WS/T 586—2018, Screening for overweight and obesity among school-age
497 children and adolescents, 2018.

498

499

500 **Table 1.** Age- and sex-specific BMI cutoff points of childhood overweight and obesity.²²

Age, years	Boys		Girls	
	Overweight	Obesity	Overweight	Obesity
8.0 - < 8.5	17.8 - < 19.7	≥ 19.7	17.6 - < 19.4	≥ 19.4
8.5 - < 9.0	18.1 - < 20.3	≥ 20.3	18.1 - < 19.9	≥ 19.9
9.0 - < 9.5	18.5 - < 20.8	≥ 20.8	18.5 - < 20.4	≥ 20.4
9.5 - < 10.0	18.9 - < 21.4	≥ 21.4	19.0 - < 21.0	≥ 21.0
10.0 - < 10.5	19.2 - < 21.9	≥ 21.9	19.5 - < 21.5	≥ 21.5
10.5 - < 11.0	19.6 - < 22.5	≥ 22.5	20.0 - < 22.1	≥ 22.1
11.5 - 12.0	19.9 - < 23.0	≥ 23.0	20.5 - < 22.7	≥ 22.7

501

502

503 **Figure 1** Schedule of enrollment, allocation, interventions, and assessments.

	Enrolment	Allocation	Run-in		Intervention			Follow-up		
Timepoint, week	-	-	1	2	4	8	12	24	36	48
Enrolment										
Informed consent	x									
Eligibility screen	x									
Baseline assessment	x									
Allocation		x								
Intervention										
Light-intensity exercise			x	x	x	x	x			
Moderate-intensity exercise			x	x	x	x	x			
Intermittent vigorous exercise			x	x	x	x	x			
Assessment										
Adiposity		x			x	x	x	x	x	x
Sexual hormones		x			x	x	x	x	x	x
Body compositions		x			x	x	x	x	x	x
Cardiopulmonary function		x			x	x	x	x	x	x
Biochemical measurement		x			x	x	x	x	x	x
Exercise performance		x					x			x
Hepatic hemodynamic index		x					x			x
Bone mineral density		x					x			x
Inflammatory biomarkers		x					x			x
Thyroid function		x					x			x
Oxidative stress biomarkers		x					x			x
Oral and gut microbiota		x					x			x
Blood and faecal metabolomics		x					x			x
Attention performance		x					x			x
Sleep quality		x					x			x
Diets and nutrients		x					x			x
Whole genome sequencing		x					x			x
Viromics		x					x			x
Proteomics		x					x			x
Volatile organic compounds in breath		x					x			x
Anthropometric measurement of the parents		x					x	x		
Whole genome sequencing of the parents;								x		
Disease history of the parents								x		

504